Dyne Therapeutics, Inc.

NasdaqGS DYN

Dyne Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

Dyne Therapeutics, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Dyne Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 157.82 M, a -36.40% change year over year.
Dyne Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 248.14 M, a -39.11% change year over year.
Dyne Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 407.52 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: DYN

Dyne Therapeutics, Inc.

CEO	Mr. John G. Cox M.B.A.
IPO Date	Sept. 17, 2020
Location	United States
Headquarters	1560 Trapelo Road
Employees	173
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Key trends

Past 5 years